Sky Bear Technical Standards - Home
Search
×
FR

Placeholder headline

This is just a placeholder headline

TEMA 2026 Edition – Online Subscription Only

$

BUY NOW

Placeholder headline

This is just a placeholder headline

API RP 15SIH, 2nd Edition: Installation and Handling of Spoolable Reinforced Plastic Line Pipe

$

158

BUY NOW

Placeholder headline

This is just a placeholder headline

API RP 754, 4th Edition: Process Safety Performance Indicators for the Refining and Petrochemical Industries

$

393

BUY NOW

Placeholder headline

This is just a placeholder headline

ASME B31.1-2020: Power Piping

$

668

BUY NOW

Placeholder headline

This is just a placeholder headline

ASME B31.1-2022: Power Piping

$

668

BUY NOW

ISO 17593:2022

ISO 17593:2022 Clinical laboratory testing and in vitro medical devices – Requirements for in vitro monitoring systems for self-testing of oral anticoagulant therapy

CDN $393.00

SKU: 84af812bb951 Category:

Description

This document specifies requirements for in vitro measuring systems for self-monitoring of vitamin-K antagonist oral anticoagulation therapy, including performance, quality assurance and user training and procedures for the validation of performance by the intended users under actual and simulated conditions of use.

This document applies solely to prothrombin time measuring systems used by lay persons for monitoring their own vitamin-K antagonist oral anticoagulation therapy, and which report results as international normalized ratios (INR).

This document is applicable to manufacturers of such systems and those other organizations (e.g. regulatory authorities and conformity assessment bodies) having the responsibility for assessing the performance of these systems.

This document is not applicable to:

-    in vitro measuring systems for coagulation quantities assessing vitamin-K antagonist oral anticoagulation therapy used by physicians or healthcare providers;

-    non-vitamin-K antagonist oral anticoagulation therapy (e.g. dabigatran);

-    a comprehensive evaluation of all possible factors that can affect the performance of these systems;

-    the medical aspects of oral-anticoagulation therapy.

Edition

2

Published Date

2022-03-11

Status

PUBLISHED

Pages

53

Language Detail Icon

English

Format Secure Icon

Secure PDF

Abstract

This document specifies requirements for in vitro measuring systems for self-monitoring of vitamin-K antagonist oral anticoagulation therapy, including performance, quality assurance and user training and procedures for the validation of performance by the intended users under actual and simulated conditions of use.

This document applies solely to prothrombin time measuring systems used by lay persons for monitoring their own vitamin-K antagonist oral anticoagulation therapy, and which report results as international normalized ratios (INR).

This document is applicable to manufacturers of such systems and those other organizations (e.g. regulatory authorities and conformity assessment bodies) having the responsibility for assessing the performance of these systems.

This document is not applicable to:

-    in vitro measuring systems for coagulation quantities assessing vitamin-K antagonist oral anticoagulation therapy used by physicians or healthcare providers;

-    non-vitamin-K antagonist oral anticoagulation therapy (e.g. dabigatran);

-    a comprehensive evaluation of all possible factors that can affect the performance of these systems;

-    the medical aspects of oral-anticoagulation therapy.

Previous Editions

Can’t find what you are looking for?

Please contact us at: